research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
Search
for
Sort by
Research
240-270 / 1000+ results research Evaluation of quality of life scores and family impact scales in pediatric patients with alopecia areata: a cross‐sectional cohort study
Alopecia areata greatly affects the quality of life for children and their families.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study
Baseline severity and relapse history affect alopecia areata treatment and recurrence.
research Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata = Efficacy and safety of baricitinib treatment in alopecia areata:a retrospective analysis
Baricitinib is effective and safe for treating severe alopecia areata.
research Assessment of Vitamin D Level in Patients of Alopecia Areata
Low vitamin D levels are common in people with Alopecia Areata.
research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Etiopathogenesis of Alopecia Areata
Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.
research Hearing impairment in patients with alopecia areata
Alopecia areata may lead to hearing loss.
research Retrospective Analysis of Systemic Corticosteroids for Alopecia Areata in Pediatric Patients
Systemic steroids temporarily improve severe alopecia areata in children but often lead to relapse.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss
The updated SALT II tool offers a more precise way to measure scalp hair loss.
research Extensive alopecia areata: Not necessarily recalcitrant to therapy!
Some people with severe, long-lasting baldness responded well to a specific combination treatment.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research The Relationship Between ABO And Rh Blood Groups With Alopecia Areata
AB+ blood group is more common in alopecia areata patients.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
Baricitinib effectively regrows hair in severe alopecia areata cases.
research Serum 25-Hydroxy Vitamin D Level in Patients with Alopecia Areata and Its Relationship with Severity of the Disease
Lower vitamin D levels are linked to more severe alopecia areata.
research COMPARATIVE EFFICACY OF TOPICAL CLOBETASOL PROPIONATE 0.05% OINTMENT AND TOPICAL TACROLIMUS 0.1% OINTMENT IN THE TREATMENT OF ALOPECIA AREATA
Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
research Tofacitinib in the Recalcitrant Cases of Alopecia Areata: A Pilot Study
Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
research Serum level of calprotectin as a new inflammatory marker in patients with alopacia areata
Calprotectin levels are higher in alopecia areata patients, indicating systemic inflammation.
research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
Baricitinib is effective and safe for treating severe alopecia areata.
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research Quality of life in patients with alopecia areata: a hospital‐based cross‐sectional study
Alopecia areata significantly lowers quality of life, especially in personal and social areas, and more so if the patient is also depressed.
research Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
research Evaluation of the effect of topical calcipotriol versus platelet-rich plasma versus a combination of both on patients with Alopecia Areata
Combining calcipotriol and PRP is most effective for treating Alopecia Areata.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research Evaluation of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, CRP and ESR with disease severity in patients with alopecia areata
Higher MPV and CRP levels may indicate more severe alopecia areata.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.